These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28098570)

  • 21. Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer.
    Cheng TL; Chang MY; Huang SY; Sheu CC; Kao EL; Cheng YJ; Chong IW
    Chest; 2005 Sep; 128(3):1453-60. PubMed ID: 16162743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Over-expression of osteopontin in non-small cell lung cancers: its clinical significance].
    Hu Z; Xiao T; Lin DM; Guo SP; Zhang ZQ; Di XB; Cheng SJ; Gao YN
    Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):591-5. PubMed ID: 18210878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer.
    Kang MW; Lee ES; Yoon SY; Jo J; Lee J; Kim HK; Choi YS; Kim K; Shim YM; Kim J; Kim H
    J Int Med Res; 2011; 39(1):78-85. PubMed ID: 21672310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer.
    Selinger CI; Cooper WA; Al-Sohaily S; Mladenova DN; Pangon L; Kennedy CW; McCaughan BC; Stirzaker C; Kohonen-Corish MR
    J Thorac Oncol; 2011 Jul; 6(7):1179-89. PubMed ID: 21597389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roles of immunohistochemical staining in diagnosing pulmonary squamous cell carcinoma.
    Yan Y; Zhang YX; Fang WF; Kang SY; Zhan JH; Chen N; Hong SD; Liang WH; Tang YN; He DC; Wu X; Zhang L
    Asian Pac J Cancer Prev; 2015; 16(2):551-7. PubMed ID: 25684486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
    Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
    J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. WT1 promotes invasion of NSCLC via suppression of CDH1.
    Wu C; Zhu W; Qian J; He S; Wu C; Chen Y; Shu Y
    J Thorac Oncol; 2013 Sep; 8(9):1163-9. PubMed ID: 23945386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre.
    Conde E; Angulo B; Izquierdo E; Muñoz L; Suárez-Gauthier A; Plaza C; Dominguez N; Torres M; Madrigal L; Rubio-Viqueira B; Belda-Iniesta C; Hidalgo M; López-Ríos F
    Histopathology; 2013 Mar; 62(4):609-16. PubMed ID: 23379755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer.
    Gumustekin M; Kargi A; Bulut G; Gozukizil A; Ulukus C; Oztop I; Atabey N
    Pathol Oncol Res; 2012 Apr; 18(2):209-18. PubMed ID: 21779788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung.
    Kwon MS; Shin SH; Yim SH; Lee KY; Kang HM; Kim TM; Chung YJ
    Lung Cancer; 2007 Jul; 57(1):46-53. PubMed ID: 17350713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-205 Expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas.
    Del Vescovo V; Cantaloni C; Cucino A; Girlando S; Silvestri M; Bragantini E; Fasanella S; Cuorvo LV; Palma PD; Rossi G; Papotti M; Pelosi G; Graziano P; Cavazza A; Denti MA; Barbareschi M
    Am J Surg Pathol; 2011 Feb; 35(2):268-75. PubMed ID: 21263248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer.
    Preusser M; Streubel B; Berghoff AS; Hainfellner JA; von Deimling A; Widhalm G; Dieckmann K; Wöhrer A; Hackl M; Zielinski C; Birner P
    Histopathology; 2014 Nov; 65(5):684-92. PubMed ID: 25039982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.
    Chen YT; Chang JW; Liu HP; Yu TF; Chiu YT; Hsieh JJ; Chen YT; Chen YR; Wu HD; Huang SF
    J Thorac Oncol; 2011 Dec; 6(12):2027-35. PubMed ID: 22052229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers.
    Tsao MS; Liu N; Chen JR; Pappas J; Ho J; To C; Viallet J; Park M; Zhu H
    Lung Cancer; 1998 Apr; 20(1):1-16. PubMed ID: 9699182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer.
    Zhang D; Jin X; Wang F; Wang S; Deng C; Gao Z; Guo C
    Ann Surg Oncol; 2007 Dec; 14(12):3581-92. PubMed ID: 17899287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of TPD52 by antitumor microRNA-218 suppresses cancer cell migration and invasion in lung squamous cell carcinoma.
    Kumamoto T; Seki N; Mataki H; Mizuno K; Kamikawaji K; Samukawa T; Koshizuka K; Goto Y; Inoue H
    Int J Oncol; 2016 Nov; 49(5):1870-1880. PubMed ID: 27633630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification.
    Lee HJ; Choe G; Jheon S; Sung SW; Lee CT; Chung JH
    J Thorac Oncol; 2010 May; 5(5):649-57. PubMed ID: 20354454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance.
    Ichimura E; Maeshima A; Nakajima T; Nakamura T
    Jpn J Cancer Res; 1996 Oct; 87(10):1063-9. PubMed ID: 8957065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ZYG11A serves as an oncogene in non-small cell lung cancer and influences CCNE1 expression.
    Wang X; Sun Q; Chen C; Yin R; Huang X; Wang X; Shi R; Xu L; Ren B
    Oncotarget; 2016 Feb; 7(7):8029-42. PubMed ID: 26771237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer.
    Gately K; Forde L; Cuffe S; Cummins R; Kay EW; Feuerhake F; O'Byrne KJ
    Clin Lung Cancer; 2014 Jan; 15(1):58-66. PubMed ID: 24210543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.